ARS Pharmaceuticals, Inc. — Director's Dealing 2022

Mar 18, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Silverback Therapeutics, Inc. (SBTX)
CIK: 0001671858
Period of Report: 2021-03-03

Reporting Person: ROOT JONATHAN D (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-03	Common Stock	P	350	$52.07	Acquired	350	Indirect
2021-11-15	Common Stock	P	2014	$8.85	Acquired	2364	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2069167	Indirect
Common Stock	105012	Indirect
Common Stock	95238	Direct

Footnotes

F1: Shares are being reported following the discovery that shares of the issuer were purchased in discretionary IRA accounts held by the spouse of the reporting person. The reporting person is not an owner of such IRA accounts. The total in Column 5 of Table I does not reflect previously reported transactions that occurred after 3/3/2021.

F2: Presidio Management Group XII, L.L.C. (PMG XII), the general partner of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, USVP XII), has sole voting and dispositive power with respect to the shares held by USVP XII. The reporting person is a managing member of PMG XII, and shares voting and dispositive power with respect to the shares held by USVP XII. The reporting person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares.